Cited by 565Schizophrenia research and treatmentNeurotransmitter Receptor Influence on BehaviorParkinson's Disease Mechanisms and Treatments

The DOI matches its Crossref record; 88 of the 89 references it cites were found in a registry or an index.

Increased Synaptic Dopamine Function in Associative Regions of the Striatum in Schizophrenia

Kegeles, Lawrence S., Abi-Dargham, Anissa, Frankle, W. Gordon, Gil, Roberto, Cooper, Thomas B., Slifstein, Mark, Hwang, Dah-Ren, Huang, Yiyun, Haber, Suzanne N., Laruelle, Marc·2010·Archives of General Psychiatry

DOI 10.1001/archgenpsychiatry.2010.10

Open this paper in CoChat — free account

Abstract

CONTEXT: A long-standing version of the dopamine hypothesis of schizophrenia postulates that hyperactivity of dopaminergic transmission at D(2) receptors in the limbic striatum is associated with the illness and that blockade of mesolimbic D(2) receptors is responsible for the antipsychotic action of D(2) receptor antagonists. OBJECTIVE: To localize dopaminergic hyperactivity within the striatum in schizophrenia. DESIGN: Case-control study. SETTING: Inpatient research unit. PARTICIPANTS: Eighteen untreated patients with schizophrenia and 18 healthy control subjects matched for age, sex, ethnicity, parental socioeconomic status, cigarette smoking, and weight. MAIN OUTCOME MEASURES: Percentage change in dopamine D(2) receptor availability in striatal subregions within each subject measured by positron emission tomography with carbon 11-labeled raclopride before and during pharmacologically induced dopamine depletion. RESULTS: In the associative striatum, acute dopamine depletion resulted in a larger increase in D(2) receptor availability in patients with schizophrenia (mean [SD], 15% [7%]) than in control subjects (10% [7%], P = .045), suggesting higher synaptic dopamine concentration. Within the associative striatum, this effect was most pronounced in the precommissural dorsal caudate (15% [8%] in patients vs 9% [8%] in controls, P = .03). No between-group differences were observed in the limbic and sensorimotor striatum. CONCLUSIONS: These findings suggest that schizophrenia is associated with elevated dopamine function in associative regions of the striatum. Because the precommissural dorsal caudate processes information from the dorsolateral prefrontal cortex, this observation also suggests that elevated subcortical dopamine function might adversely affect performance of the dorsolateral prefrontal cortex in schizophrenia. On the other hand, the absence of a group difference in the limbic striatum brings into question the therapeutic relevance of the mesolimbic selectivity of second-generation antipsychotic drugs.

Integrity signals

Registry

Crossref · 10.1001/archgenpsychiatry.2010.10

Cites

88 of 88 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Parallel organization of functionally segregated circuits linking basal ganglia and cortex
Alexander, G. E., DeLong, M. R., & Strick, P. L. (1986) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.09.030186.002041 · Cited by 8,527
Four Factor Index of Social Status
Paschou, R. (1975) · Cited by 6,989
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Four Factor Index of Social Status [1975]
Hollingshead, A. B. (1975) · Cited by 5,151
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop
Parent, A., & Hazrati, L.-N. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(94)00007-c · Cited by 2,161
Dopamine in schizophrenia: a review and reconceptualization
Davis, K. L., Kahn, R. S., Ko, G., & Davidson, M. (1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.11.1474 · Cited by 2,051
Physiologic Dysfunction of Dorsolateral Prefrontal Cortex in Schizophrenia
Weinberger, D. R. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800020020004 · Cited by 2,025
Negative v Positive Schizophrenia
Andreasen, N. C. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290070025006 · Cited by 2,008

Show all 89 references

Sorted by citations

Items 101–200 of 565

Unexpected global impact of VTA dopamine neuron activation as measured by opto-fMRI
Lohani, S., Poplawsky, A. J., Kim, S.-G., & Moghaddam, B. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.102 · Cited by 89
Striatal glutamate and the conversion to psychosis: a prospective 1H-MRS imaging study.
de la Fuente-Sandoval, C., León-Ortíz, P., Azcárraga, M., Favila, R., Stephano, S., & Graff-Guerrero, A. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000314 · Cited by 88
The Cross-Talk Between the Dopaminergic and the Immune System Involved in Schizophrenia
Vidal, P. M., & Pacheco, R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00394 · Cited by 92
Positive priming and intentional binding: Eye-blink rate predicts reward information effects on the sense of agency
Aarts, H., Bijleveld, E., Custers, R., Dogge, M., Deelder, M., Schutter, D. J. L. G., & van Haren, N. E. M. (2011) · Social Neuroscience · doi:10.1080/17470919.2011.590602 · Cited by 95
The other side of the histamine H3 receptor
Ellenbroek, B. A., & Ghiabi, B. (2014) · Trends in Neurosciences · doi:10.1016/j.tins.2014.02.007 · Cited by 83
Synergistic interactions between PDE4B and GSK-3: DISC1 mutant mice
Lipina, T. V., Wang, M., Liu, F., & Roder, J. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.02.020 · Cited by 83
Schizophrenia and Depression Co-Morbidity: What We have Learned from Animal Models
Samsom, J., & Wong, A. H. C. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00013 · Cited by 88
Neurobiological basis of motivational deficits in psychopathology
Salamone, J. D., Koychev, I. G., Correa, M., & McGuire, P. K. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.08.014 · Cited by 87
Heterogeneity in Dopamine Neuron Synaptic Actions Across the Striatum and Its Relevance for Schizophrenia
Chuhma, N., Mingote, S., Kalmbach, A., Yetnikoff, L., & Rayport, S. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.07.002 · Cited by 93
Dopamine, fronto-striato-thalamic circuits and risk for psychosis.
Dandash, O., Pantelis, C., & Fornito, A. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2016.08.020 · Cited by 89
Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain
Purves-Tyson, T. D., Owens, S. J., Rothmond, D. A., Halliday, G. M., Double, K. L., Stevens, J., McCrossin, T., & Weickert, C. S. (2017) · Translational Psychiatry · doi:10.1038/tp.2016.257 · Cited by 81
Abnormal Striatal Dopamine Transmission in Schizophrenia
Brunelin, J., Fecteau, S., & Suaud-Chagny, M. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320030011 · Cited by 90
Measuring the construct of executive control in schizophrenia: Defining and validating translational animal paradigms for discovery research
Gilmour, G., Arguello, P. A., Bari, A., Brown, V. J., Carter, C., Floresco, S., Jentsch, J. D., Tait, D. S., Young, J. W., & Robbins, T. W. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.04.006 · Cited by 81
Prefrontal Cortex Dysfunction Increases Susceptibility to Schizophrenia-Like Changes Induced by Adolescent Stress Exposure
Gomes, F. V., & Grace, A. (2016) · Schizophrenia bulletin · doi:10.1093/schbul/sbw156 · Cited by 84
Adolescent Stress as a Driving Factor for Schizophrenia Development-A Basic Science Perspective.
Gomes, F. V., & Grace, A. (2017) · Schizophrenia bulletin · doi:10.1093/schbul/sbx033 · Cited by 73
Abnormal relationship between medial temporal lobe and subcortical dopamine function in people with an ultra high risk for psychosis.
Allen, P., Chaddock, C. A., Howes, O., Egerton, A., Seal, M., Fusar-Poli, P., Valli, I., Day, F., & McGuire, P. (2012) · Schizophrenia bulletin · doi:10.1093/schbul/sbr017 · Cited by 87
Effects of lisdexamfetamine and s-citalopram, alone and in combination, on effort-related choice behavior in the rat
Yohn, S. E., López‐Cruz, L., Hutson, P. H., Correa, M., & Salamone, J. D. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4176-7 · Cited by 76
The dopamine transporter role in psychiatric phenotypes
Salatino‐Oliveira, A., Rohde, L. A., & Hutz, M. H. (2017) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32578 · Cited by 73
Systems Biology of Phenotypic Robustness and Plasticity
Nijhout, H. F., Sadre‐Marandi, F., Best, J. A., & Reed, M. C. (2017) · Integrative and Comparative Biology · doi:10.1093/icb/icx076 · Cited by 71
Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia
Oda, Y., Kanahara, N., & Iyo, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226228 · Cited by 74
Reduced Structural Connectivity in Frontostriatal White Matter Tracts in the Associative Loop in Schizophrenia
Levitt, J. J., Nestor, P. G., Levin, L. K., Pelavin, P. E., Lin, P., Kubicki, M. R., McCarley, R. W., Shenton, M. E., & Yogesh Rathi, A. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16091046 · Cited by 71
Imaging-Based Neurochemistry in Schizophrenia: A Systematic Review and Implications for Dysfunctional Long-Term Potentiation
Salavati, B., Rajji, T. K., Price, R., Sun, Y., Graff‐Guerrero, A., & Daskalakis, Z. J. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu132 · Cited by 71
Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant Schizophrenia
McQueen, G., Sendt, K.-V., Gillespie, A. L., Avila, A., Lally, J., Vallianatou, K., Chang, N., Ferreira, D., Borgan, F., Howes, O. D., et al. (2020) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa156 · Cited by 74
Reduced striatal dopamine synthesis capacity in patients with schizophrenia during remission of positive symptoms
Avram, M., Brandl, F., Cabello, J., Leucht, C., Scherr, M., Mustafa, M., Leucht, S., Ziegler, S. I., & Sorg, C. (2019) · Brain · doi:10.1093/brain/awz093 · Cited by 64
The Dopamine Dysfunction in Schizophrenia Revisited: New Insights into Topography and Course
Kuepper, R., Skinbjerg, M., & Abi‐Dargham, A. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25761-2_1 · Cited by 65
Self-citation
Imaging Changes in Glutamate Transmission In Vivo with the Metabotropic Glutamate Receptor 5 Tracer [11C] ABP688 and N-Acetylcysteine Challenge
Miyake, N., Skinbjerg, M., Easwaramoorthy, B., Kumar, D. J. S., Girgis, R. R., Xu, X., Slifstein, M., & Abi‐Dargham, A. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.12.023 · Cited by 67
Self-citation
Cognition dopamine and bioactive lipids in schizophrenia
Yao, J. K. (2010) · Frontiers in Bioscience-Scholar · doi:10.2741/s153 · Cited by 67
Role of netrin-1 in the organization and function of the mesocorticolimbic dopamine system
Flores, C. (2011) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.100171 · Cited by 72
Elevated Striatal Dopamine Function in Immigrants and Their Children: A Risk Mechanism for Psychosis
Egerton, A., Howes, O. D., Houle, S., McKenzie, K. J., Valmaggia, L., Bagby, M. R., Tseng, H., Bloomfield, M., Kenk, M., Bhattacharyya, S., et al. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw181 · Cited by 72
The role of dopamine D 3 receptors in the mechanism of action of cariprazine
Calabrese, F., Tarazi, F. I., Racagni, G., & Riva, M. A. (2019) · CNS Spectrums · doi:10.1017/s109285291900083x · Cited by 66
Dysfunctional Striatal Systems in Treatment-Resistant Schizophrenia
White, T. P., Wigton, R. L., Joyce, D. W., Collier, T., Fornito, A., & Shergill, S. S. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.277 · Cited by 64
From the prodrome to chronic schizophrenia: the neurobiology underlying psychotic symptoms and cognitive impairments
Howes, O. D., Fusar-Poli, P., Bloomfield, M. P., Selvaraj, S., & McGuire, P. (2012) · Current pharmaceutical design · doi:10.2174/138161212799316217 · Cited by 61
Escape from homeostasis
Nijhout, H. F., Best, J. A., & Reed, M. C. (2014) · Mathematical Biosciences · doi:10.1016/j.mbs.2014.08.015 · Cited by 62
Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study
Tarumi, R., Tsugawa, S., Noda, Y., Plitman, E., Honda, S., Matsushita, K., Chavez, S., Sawada, K., Wada, M., Matsui, M., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0589-z · Cited by 56
Increased Release of Dopamine in the Striata of Young Adults With Hearing Impairment and Its Relevance for the Social Defeat Hypothesis of Schizophrenia
Gevonden, M. J., Booij, J., van den Brink, W., Heijtel, D., van Os, J., & Selten, J. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1325 · Cited by 62
Cognition-Emotion Dysinteraction in Schizophrenia
Anticevic, A., & Corlett, P. R. (2012) · Frontiers in Psychology · doi:10.3389/fpsyg.2012.00392 · Cited by 66
Subcortical Dopamine and Cognition in Schizophrenia: Looking Beyond Psychosis in Preclinical Models
Conn, K., Burne, T. H. J., & Kesby, J. P. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00542 · Cited by 66
A potential biomarker for treatment stratification in psychosis: evaluation of an [18F] FDOPA PET imaging approach
Veronese, M., Santangelo, B., Jauhar, S., D’Ambrosio, E., Demjaha, A., Salimbeni, H., Jin, H., McCrone, P., Turkheimer, F., & Howes, O. D. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00866-7 · Cited by 58
Brain insulin action in schizophrenia: Something borrowed and something new
Agarwal, S. M., Caravaggio, F., Costa-Dookhan, K. A., Castellani, L. N., Kowalchuk, C., Asgariroozbehani, R., Graff‐Guerrero, A., & Hahn, M. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.05.010 · Cited by 64
Aberrant Functional Connectivity in the Default Mode and Central Executive Networks in Subjects with Schizophrenia – A Whole-Brain Resting-State ICA Study
Littow, H., Huossa, V., Karjalainen, S., Jääskeläinen, E., Haapea, M., Miettunen, J., Tervonen, O. A., Isohanni, M. K., Nikkinen, J., Veijola, J. M., et al. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00026 · Cited by 64
Striatal dopamine, reward, and decision making in schizophrenia
Deserno, L., Schlagenhauf, F., & Heinz, A. (2016) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2016.18.1/ldeserno · Cited by 58
Dopamine and executive function: Increased spontaneous eye blink rates correlate with better set-shifting and inhibition, but poorer updating
Zhang, T., Mou, D., Wang, C., Tan, F., Jiang, Y., Lijun, Z., & Li, H. (2015) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2015.04.010 · Cited by 57
Striosomes control dopamine via dual pathways paralleling canonical basal ganglia circuits
Lazaridis, I., Crittenden, J. R., Ahn, G., Hirokane, K., Wickersham, I. R., Yoshida, T., Mahar, A., Skara, V., Loftus, J., Parvataneni, K., et al. (2024) · Current Biology · doi:10.1016/j.cub.2024.09.070 · Cited by 58
Glutamatergic Metabolites, Volume and Cortical Thickness in Antipsychotic-Naive Patients with First-Episode Psychosis: Implications for Excitotoxicity
Plitman, E., Patel, R., Chung, J. K., Pipitone, J., Chavez, S., Reyes-Madrigal, F., Gómez-Cruz, G., León-Ortíz, P., Chakravarty, M. M., de la Fuente‐Sandoval, C., et al. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.84 · Cited by 55
Imaging dopamine transmission in the frontal cortex: a simultaneous microdialysis and [11C]FLB 457 PET study
Narendran, R., Jedema, H. P., Lopresti, B. J., Mason, N. S., Gurnsey, K., Ruszkiewicz, J., Chen, C.-M., Deuitch, L., Frankle, W. G., & Bradberry, C. W. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.9 · Cited by 54
Self-citation
Multiple D2 heteroreceptor complexes: new targets for treatment of schizophrenia
Borroto‐Escuela, D. O., Pintšuk, J., Schäfer, T., Friedland, K., Ferraro, L., Tanganelli, S., Liu, F., & Fuxé, K. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316637570 · Cited by 56
Approaches to neuromodulation for schizophrenia
Gault, J., Davis, R. A., Cascella, N. G., Saks, E. R., Corripio, I., Anderson, W. S., D, A. O. M., Thompson, J. A., Pomarol‐Clotet, E., Sawa, A., et al. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316946 · Cited by 57
Glycine Signaling in the Framework of Dopamine-Glutamate Interaction and Postsynaptic Density. Implications for Treatment-Resistant Schizophrenia
de Bartolomeis, A., Manchia, M., Marmo, F., Vellucci, L., Iasevoli, F., & Barone, A. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00369 · Cited by 54
Association between schizophrenia and genetic variation in DCC: a case–control study
Grant, A., Fathalli, F., Rouleau, G., Joober, R., & Flores, C. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.02.023 · Cited by 53
How changes in dopamine D2 receptor levels alter striatal circuit function and motivation
Simpson, E. H., Gallo, E. F., Balsam, P. D., Javitch, J. A., & Kellendonk, C. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01253-4 · Cited by 54
Divergent activation of ventromedial and ventrolateral dopamine systems in animal models of amphetamine sensitization and schizophrenia
Lodge, D., & Grace, A. (2011) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000113 · Cited by 52
BMI Modulates Calorie-Dependent Dopamine Changes in Accumbens from Glucose Intake
Wang, G., Tomasi, D. G., Convit, A. J., Logan, J., Wong, C., Shumay, E., Fowler, J. S., & Volkow, N. D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101585 · Cited by 55
Presynaptic Dopamine in Schizophrenia
Miyake, N., Thompson, J. L., Skinbjerg, M., & Abi‐Dargham, A. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00230.x · Cited by 58
Self-citation
Functional Connectivity of Corticostriatal Circuitry and Psychosis-like Experiences in the General Community
Sabaroedin, K., Tiego, J., Parkes, L., Sforazzini, F., Finlay, A., Johnson, B. P., Pinar, A., Cropley, V., Harrison, B. J., Zalesky, A., et al. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.02.013 · Cited by 54
Emerging drugs for schizophrenia: an update
Köster, L.-S., Carbon, M., & Correll, C. U. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.958148 · Cited by 55
Neuropathological changes in the substantia nigra in schizophrenia but not depression
Williams, M. R., Galvin, K., OSullivan, B., Macdonald, C., Ching, E. W.-K., Turkheimer, F., Howes, O. D., Pearce, R. K. B., Hirsch, S. R., & Maier, M. (2013) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-013-0479-z · Cited by 52
Activation of the mGlu1 metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M4 muscarinic receptor allosteric modulators
Yohn, S. E., Foster, D. J., Covey, D. P., Moehle, M. S., Galbraith, J., García-Barrantes, P. M., Cho, H. P., Bubser, M., Blobaum, A. L., Joffe, M. E., et al. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0206-2 · Cited by 52
A novel dopamine D1 receptor agonist excites delay-dependent working memory-related neuronal firing in primate dorsolateral prefrontal cortex
Wang, M., Datta, D., Enwright, J. F., Galvin, V. C., Yang, S., Paspalas, C. D., Kozak, R., Gray, D. L., Lewis, D. A., & Arnsten, A. F. T. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.03.001 · Cited by 55
Neurosurgery for schizophrenia: an update on pathophysiology and a novel therapeutic target
Mikell, C. B., Sinha, S. R., & Sheth, S. A. (2015) · Journal of neurosurgery · doi:10.3171/2015.4.jns15120 · Cited by 53
The Dopamine Hypothesis of Schizophrenia
Gründer, G., & Cumming, P. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801829-3.00015-x · Cited by 57
Striatal function in relation to negative symptoms in schizophrenia
Ehrlich, S., Yendiki, A., Greve, D. N., Manoach, D. S., Ho, B., White, T. J. H., Schulz, S. C., GOFF, D. C., Gollub, R. L., & Holt, D. J. (2011) · Psychological Medicine · doi:10.1017/s003329171100119x · Cited by 50
5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice
Pogorelov, V. M., Rodriguiz, R. M., Cheng, J., Huang, M., Schmerberg, C. M., Meltzer, H. Y., Roth, B. L., Kozikowski, A. P., & Wetsel, W. C. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.52 · Cited by 52
Using pupil dilation, eye-blink rate, and the value of mother to investigate reward learning mechanisms in infancy
Tummeltshammer, K. S., Feldman, E. C. H., & Amso, D. (2018) · Developmental Cognitive Neuroscience · doi:10.1016/j.dcn.2018.12.006 · Cited by 52
A Highly Selective Implantable Electrochemical Fiber Sensor for Real-Time Monitoring of Blood Homovanillic Acid
Zou, K., Li, Q., Li, D., Jiao, Y., Wang, L., Li, L., Wang, J., Li, Y., Gao, R., Li, F., et al. (2024) · ACS Nano · doi:10.1021/acsnano.3c11641 · Cited by 49
Bridging Levels of Understanding in Schizophrenia Through Computational Modeling
Anticevic, A., Murray, J. D., & Barch, D. M. (2015) · Clinical Psychological Science · doi:10.1177/2167702614562041 · Cited by 51
Altered Brain Network Connectivity as a Potential Endophenotype of Schizophrenia
Li, P., Fan, T., Zhao, R., Han, Y., Shi, L., Sun, H., Chen, S., Shi, J., Lin, X., & Lü, L. (2017) · Scientific Reports · doi:10.1038/s41598-017-05774-3 · Cited by 50
Hippocampal Hyperactivity as a Druggable Circuit-Level Origin of Aberrant Salience in Schizophrenia
Kätzel, D., Wolff, A. R., Bygrave, A. M., & Bannerman, D. M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.486811 · Cited by 51
Reductions in midbrain GABAergic and dopamine neuron markers are linked in schizophrenia
Purves-Tyson, T. D., Brown, A. M., Weissleder, C., Rothmond, D. A., & Weickert, C. S. (2021) · Molecular Brain · doi:10.1186/s13041-021-00805-7 · Cited by 47
Neuroimaging findings in schizotypal personality disorder: A systematic review
Fervaha, G., & Remington, G. J. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.11.014 · Cited by 50
Frontostriatothalamic effective connectivity and dopaminergic function in the psychosis continuum
Sabaroedin, K., Razi, A., Chopra, S., Tran, N., Pozaruk, A., Chen, Z.-L., Finlay, A., Nelson, B., Allott, K., Alvarez-Jimenez, M., et al. (2022) · Brain : a journal of neurology · doi:10.1093/brain/awac018 · Cited by 43
Selective Augmentation of Striatal Functional Connectivity Following NMDA Receptor Antagonism: Implications for Psychosis
Dandash, O., Harrison, B. J., Adapa, R., Gaillard, R., Giorlando, F., Wood, S. J., Fletcher, P. C., & Fornito, A. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.210 · Cited by 47
Psychopharmacological treatment of schizophrenia: What do we have, and what could we get?
Ellenbroek, B. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.03.013 · Cited by 46
Insights About Striatal Circuit Function and Schizophrenia From a Mouse Model of Dopamine D2 Receptor Upregulation
Simpson, E. H., & Kellendonk, C. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.07.004 · Cited by 44
The frontal cortex as a network hub controlling mood and cognition: Probing its neurochemical substrates for improved therapy of psychiatric and neurological disorders
Millan, M. J., Rivet, J., & Gobert, A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116672342 · Cited by 44
Subcortical shape analysis of progressive mild cognitive impairment in Parkinson's disease
Chung, S. J., Shin, J., Cho, K. H., Lee, Y., Sohn, Y. H., Seong, J., & Lee, P. H. (2017) · Movement Disorders · doi:10.1002/mds.27106 · Cited by 45
Meta‐analytic evidence for altered mesolimbic responses to reward in schizophrenia
Chase, H. W., Loriemi, P., Wensing, T., Eickhoff, S. B., & Nickl‐Jockschat, T. (2018) · Human Brain Mapping · doi:10.1002/hbm.24049 · Cited by 45
Striatal Dopamine Transporter Availability in Drug-Naive Patients With Schizophrenia: A Case-Control SPECT Study With [99mTc]-TRODAT-1 and a Meta-Analysis
Chen, K. C., Yang, Y. K., Howes, O. D., Lee, I. H., Landau, S., Yeh, T. L., Chiu, N. T., Chen, P. S., Lu, R., David, A. S., et al. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr163 · Cited by 44
Measuring Dopamine Synaptic Transmission with Molecular Imaging and Pharmacological Challenges: The State of the Art
Laruelle, M. A. (2012) · Neuromethods · doi:10.1007/7657_2012_45 · Cited by 43
Self-citation
α2-Adrenoceptors are targets for antipsychotic drugs
Brosda, J., Jantschak, F., & Pertz, H. H. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3459-8 · Cited by 45
Psychosis spectrum illnesses as disorders of prefrontal critical period plasticity
Vinogradov, S., Chafee, M. V., Lee, E. G., & Morishita, H. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01451-w · Cited by 44
Elevated Excitatory Input to the Nucleus Accumbens in Schizophrenia: A Postmortem Ultrastructural Study
McCollum, L. A., Walker, C. K., Roche, J. K., & Roberts, R. C. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv030 · Cited by 42
Ventral Striatal Dysfunction and Symptom Expression in Individuals With Schizotypal Personality Traits and Early Psychosis
Kirschner, M., Hager, O. M., Muff, L., Bischof, M., Hartmann-Riemer, M. N., Kluge, A., Habermeyer, B., Seifritz, E., Tobler, P. N., & Kaiser, S. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw142 · Cited by 46
New approaches to the management of schizophrenia: focus on aberrant hippocampal drive of dopamine pathways
Lodge, D. J., & Perez, S. M. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s42708 · Cited by 42
Prefrontal and Striatal Dopamine Release Are Inversely Correlated in Schizophrenia
Frankle, W. G., Himes, M. L., Mason, N. S., Mathis, C. A., & Narendran, R. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.05.009 · Cited by 44
Self-citation
Unraveling the genetic architecture of copy number variants associated with schizophrenia and other neuropsychiatric disorders
Rutkowski, T. P., Schroeder, J. P., Gafford, G. M., Warren, S. T., Weinshenker, D., Caspary, T., & Mullé, J. G. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23970 · Cited by 40
The role of dopamine dysregulation and evidence for the transdiagnostic nature of elevated dopamine synthesis in psychosis: a positron emission tomography (PET) study comparing schizophrenia, delusional disorder, and other psychotic disorders
Cheng, C. P.-W., Chang, W. C., Lo, G. G., Chan, K. W. S., Lee, E. H. M., Hui, L. M. C., Suen, Y. N., Leung, Y. L., Yeung, K. M. P. A., Chen, S., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0740-x · Cited by 40
Are dopamine D2 receptors out of control in psychosis?
Seeman, P. M. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.07.006 · Cited by 42
Endocannabinoids and Schizophrenia
Desfossés, J., Stip, É., Bentaleb, L. A., & Potvin, S. (2010) · Pharmaceuticals · doi:10.3390/ph3103101 · Cited by 42
Neural activity changes in unaffected children of patients with schizophrenia: A resting-state fMRI study
Tang, Y., Chen, K., Zhou, Y., Liu, J., Wang, Y., Driesen, N. R., Edmiston, E. K., Chen, X., Jiang, X., Kong, L., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.07.025 · Cited by 39
Emerging Roles of FTO in Neuropsychiatric Disorders
Chang, R., Huang, Z., Zhao, S., Zou, J., Li, Y., & Tan, S. (2022) · BioMed Research International · doi:10.1155/2022/2677312 · Cited by 39
Nature or Nurture? Determining the Heritability of Human Striatal Dopamine Function: an [18F]-DOPA PET Study
Stokes, P. R. A., Shotbolt, P., Mehta, M. A., Turkheimer, E., Benecke, A., Copeland, C., Turkheimer, F. E., Lingford-Hughes, A. R., & Howes, O. D. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.207 · Cited by 37
Non-invasive imaging in experimental medicine for drug development
Matthews, P. M., Rabiner, I., & Gunn, R. N. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.04.009 · Cited by 39
Changes in extra-striatal functional connectivity in patients with schizophrenia in a psychotic episode
Peters, H., Riedl, V., Manoliu, A., Scherr, M., Schwerthöffer, D., Zimmer, C., Förstl, H., Bäuml, J., Sorg, C., & Koch, K. (2016) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.114.151928 · Cited by 37
Aberrant striatal dopamine links topographically with cortico-thalamic dysconnectivity in schizophrenia
Avram, M., Brandl, F., Knolle, F., Cabello, J., Leucht, C., Scherr, M., Mustafa, M., Koutsouleris, N., Leucht, S., Ziegler, S. I., et al. (2020) · Brain · doi:10.1093/brain/awaa296 · Cited by 38
Glutamate and Psychosis Risk
Egerton, A., Fusar-Poli, P., & M. Stone, J. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799316244 · Cited by 36
Striatal D2/3 Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome
Wulff, S., Pinborg, L., Svarer, C., Jensen, L. T., Nielsen, M., Allerup, P., Bak, N., Rasmussen, H., Frandsen, E., Rostrup, E., et al. (2015) · Schizophrenia bulletin · doi:10.1093/schbul/sbu220 · Cited by 45
Aberrant spontaneous neural activity and correlation with evoked-brain potentials in first-episode, treatment-naïve patients with deficit and non-deficit schizophrenia
Li, Z., Lei, W., Deng, W., Zheng, Z., Li, M., Ma, X., Wang, Q., Huang, C., Li, N., Collier, D. A., et al. (2017) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2017.01.001 · Cited by 36
Functional dysconnectivity of the limbic loop of frontostriatal circuits in first‐episode, treatment‐naive schizophrenia
Lin, P., Wang, X., Zhang, B., Kirkpatrick, B. W., Öngür, D., Levitt, J. J., Jovicich, J., Yao, S., & Wang, X. (2017) · Human Brain Mapping · doi:10.1002/hbm.23879 · Cited by 35
Unique Molecular Regulation of Higher-Order Prefrontal Cortical Circuits: Insights into the Neurobiology of Schizophrenia
Datta, D., & Arnsten, A. F. T. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00505 · Cited by 38
The PPARα agonist fenofibrate attenuates disruption of dopamine function in a maternal immune activation rat model of schizophrenia
Felice, M. D., Melis, M., Aroni, S., Muntoni, A. L., Fanni, S., Frau, R., Devoto, P., & Pistis, M. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13087 · Cited by 39

Authors: Kegeles, L. S., Abi-Dargham, A., Frankle, W. G., Gil, R., Cooper, T. B., Slifstein, M., Hwang, D.-R., Huang, Y., Haber, S. N., & Laruelle, M.
Affiliations: Columbia University Irving Medical Center (US)
ORCID: Kegeles, Lawrence S.
Frankle, W. Gordon
Cooper, Thomas B.
Slifstein, Mark
Huang, Yiyun
Haber, Suzanne N.
Venue: Archives of General Psychiatry
Publisher: American Medical Association (AMA)
Published: 2010-03-01
Volume: 67
Issue: 3
Pages: 231
ISSN: 0003-990X (ISSN-L)
DOI: 10.1001/archgenpsychiatry.2010.10
OpenAlex: W1999984108
Cited by: 565
References: 89
Citations by year: 2026: 17 · 2025: 26 · 2024: 33 · 2023: 25 · 2022: 42 · 2021: 23 · 2020: 32 · 2019: 42 · 2018: 32 · 2017: 38 · 2016: 45 · 2015: 41 · 2014: 47 · 2013: 32 · 2012: 47
FWCI: 25.78
Type: journal article
Language: en
Open access: closed
Locations: Archives of General Psychiatry (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute of Mental Health (K02MH01603-01, K02MH001603, R01MH054192)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Keywords: schizophrenia, synaptic dopamine, associative striatum, dorsal caudate, dopamine depletion, mesolimbic dopamine system, dopamine hypothesis of schizophrenia, atypical antipsychotics, dorsolateral prefrontal cortex, positron emission tomography, raclopride
MeSH terms: Adult, Brain Mapping, Carbon Radioisotopes, Caudate Nucleus, Corpus Striatum, Dopamine, Female, Humans, Image Processing, Computer-Assisted, Male, Synaptic Transmission, Putamen, Schizophrenia, Synapses, Case-Control Studies, Prefrontal Cortex, Receptors, Dopamine D2, alpha-Methyltyrosine, Raclopride, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Increased Synaptic Dopamine Function in Associative Regions of the Striatum in Schizophrenia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks